Tesamorelin half-life depends on the formulation. Current FDA prescribing information reports a mean elimination half-life of approximately 8 minutes for Egrifta SV and 11 minutes for Egrifta WR after subcutaneous administration.
Tesamorelin: Halflife Labs records ~8 min (Egrifta SV) / ~11 min (Egrifta WR) SC for SC. Evidence classification: FDA-approved product or prescribing-label source. Source summary: FDA Egrifta SV and Egrifta WR prescribing information.
Limitation: This is a population-level source statement, not a measured concentration or individualized prediction. Scientific review is documented on this page; the limited reviewer scope is defined on the About page.
Stable record ID: hlc:tesamorelin · Page revision: 2026-06-13 · Open the primary source
Egrifta SV: the 2024 FDA label reports a mean elimination half-life of approximately 8 minutes. Egrifta WR: the 2025 FDA label reports approximately 11 minutes. These values should not be collapsed into one generic tesamorelin half-life.
These are population-level label statements after subcutaneous administration. They are not measured concentrations for an individual, and a remaining-level estimate must identify the formulation and half-life assumption used.
No tesamorelin curve should be presented as measured concentration. Any curve must be explicitly labeled as a mathematical estimate and tied to a named formulation, route, source, and half-life assumption.